mhurhangee/ep-ind-claims huggingface dataset:
Control circuit, which is configured to apply to a piezoelectric transformer a voltage with a periodic shape, the period duration of which is fixed by a control frequency, the control circuit having an inductor and a control unit, and the control unit being configured to adapt the control frequency of the applied voltage as a function of an average current intensity of a current flowing through the inductor, characterized in that the control circuit is configured firstly to apply to the piezoelectric transformer a voltage with a control frequency which is below an antiresonant frequency of the piezoelectric transformer, wherein the control frequency is then gradually reduced until the average current intensity of a current flowing through the inductor exceeds a predetermined limit value.
An apparatus configured to be employed within a Network Manager, NM, (302;402;502) characterised by comprising: means for outputting a network manager, NM, subscription request generated at the NM (302;402;502), to an element manager, EM, (306;404;504) in a network function virtualization, NFV, network (300;400;500) having one or more virtual network function, VNF, instances associated therewith, wherein the NM subscription request comprises a request to subscribe to a notification associated with a virtualization resources, VR, performance measurement, PM, data of a VNF instance of the one or more VNF instances, wherein the VNF instance implements a network function associated with an evolved packet core, EPC, network; and means for processing an EM subscription response received from the EM (306;404;504), in response to the NM subscription request, wherein the EM subscription response comprises information on a result of the subscription. means for outputting a network manager, NM, subscription request generated at the NM (302;402;502), to an element manager, EM, (306;404;504) in a network function virtualization, NFV, network (300;400;500) having one or more virtual network function, VNF, instances associated therewith, wherein the NM subscription request comprises a request to subscribe to a notification associated with a virtualization resources, VR, performance measurement, PM, data of a VNF instance of the one or more VNF instances, wherein the VNF instance implements a network function associated with an evolved packet core, EPC, network; and means for processing an EM subscription response received from the EM (306;404;504), in response to the NM subscription request, wherein the EM subscription response comprises information on a result of the subscription.
An outsole (5a, 51b, 52b) being formed from a viscoelastic body containing a rubber component, characterized by the viscoelastic body having a loss factor [tan δ] measured by a dynamic viscoelasticity measurement under conditions of a temperature of 23°C, a frequency of 10 Hz, a static strain of 10%, and a dynamic strain of 7% being 0.17 or more, a storage elastic modulus [E'] measured by the dynamic viscoelasticity measurement being 5.7 MPa or less, and a ratio of a tensile stress at 300% elongation to a tensile stress at 100% elongation [M300/M100] being 4.4 or more.
An ophthalmologic apparatus for detecting an interested site of an eye fundus comprising: a front image acquiring device configured to acquire a front image of a fundus of a subject's eye, the front image being a frame of a moving image obtained by repeatedly digitally photographing the fundus illuminated with near infrared light; a search processor designated in the following as first search processor configured to search for an interested region, which is a region of interest, corresponding to an interested site of the fundus based on a brightness variation in the front image, and to generate and record interested region position information indicating a position of said interested region in the event that said interested region has been detected based on the brightness variation; a further search processor designated in the following as second search processor configured to search for said interested region by template matching between the front image and a template image in the event that said interested region has not been detected by the first search processor, and to generate and record interested region position information indicating a position of said interested region in the event that said interested region has been detected by the template matching; and a further search processor designated in the following as third search processor configured to detect a blood vessel region corresponding to a blood vessel of the fundus by analyzing the front image and search for said interested region based on a distribution of the blood vessel region in the event that said interested region has not been detected by the second search processor, and to generate and record position information indicating a position of said interested region in the event that said interested region has been detected based on the distribution of the blood vessel region. a front image acquiring device configured to acquire a front image of a fundus of a subject's eye, the front image being a frame of a moving image obtained by repeatedly digitally photographing the fundus illuminated with near infrared light; a search processor designated in the following as first search processor configured to search for an interested region, which is a region of interest, corresponding to an interested site of the fundus based on a brightness variation in the front image, and to generate and record interested region position information indicating a position of said interested region in the event that said interested region has been detected based on the brightness variation; a further search processor designated in the following as second search processor configured to search for said interested region by template matching between the front image and a template image in the event that said interested region has not been detected by the first search processor, and to generate and record interested region position information indicating a position of said interested region in the event that said interested region has been detected by the template matching; and
A method of perfusing an ex-vivo organ or tissue, the method comprising: flowing a perfusion liquid into a chamber of a bubble trap under fluctuating pressure, the chamber including at least one liquid inlet opening, a gas outlet opening, and at least one liquid outlet opening (270, 290), wherein a liquid level sensor is provided to detect the level of liquid in the chamber of the bubble trap; maintaining at least a minimum volume of the gas in the chamber sufficient to dampen pressure fluctuations of the perfusion liquid by controlling at least one valve for the openings to continuously maintain the volume of the gas in the chamber at about 75% to 95% of a total volume of the chamber while perfusing the organ or tissue; allowing the perfusion liquid with reduced pressure fluctuations to flow out of the chamber; and perfusing the organ or tissue with the reduced pressure fluctuation liquid; wherein the minimum volume of the gas is sufficient to cause a ratio of pressure fluctuations of the perfusion liquid flowing into the chamber and pressure fluctuations of the perfusion liquid flowing out of the chamber to be more than 10 to 1; and wherein the at least one valve is further controlled by means of a controller, which is in communication with the liquid level sensor, to maintain a level of the perfusion liquid in the chamber between 1 and 15 mm below the bottom of the gas outlet opening. flowing a perfusion liquid into a chamber of a bubble trap under fluctuating pressure, the chamber including at least one liquid inlet opening, a gas outlet opening, and at least one liquid outlet opening (270, 290), wherein a liquid level sensor is provided to detect the level of liquid in the chamber of the bubble trap; maintaining at least a minimum volume of the gas in the chamber sufficient to dampen pressure fluctuations of the perfusion liquid by controlling at least one valve for the openings to continuously maintain the volume of the gas in the chamber at about 75% to 95% of a total volume of the chamber while perfusing the organ or tissue; allowing the perfusion liquid with reduced pressure fluctuations to flow out of the chamber; and perfusing the organ or tissue with the reduced pressure fluctuation liquid; wherein the minimum volume of the gas is sufficient to cause a ratio of pressure fluctuations of the perfusion liquid flowing into the chamber and pressure fluctuations of the perfusion liquid flowing out of the chamber to be more than 10 to 1; and wherein the at least one valve is further controlled by means of a controller, which is in communication with the liquid level sensor, to maintain a level of the perfusion liquid in the chamber between 1 and 15 mm below the bottom of the gas outlet opening.
A liquid pharmaceutical composition formulated for administration through a nasal mucosal membrane comprising a therapeutic agent and an alkoxypolyethylene glycol represented by Formula I R-O-(CH 2 CH 2 O) n -H, wherein R is methyl; and n is a number in the range of from about 1 to about 25, and wherein the therapeutic agent is a benzodiazepine or a pharmaceutically acceptable salt thereof.
A turbine engine comprising a shaft assembly, wherein the turbine engine includes a fan or propeller assembly and an engine core, and further wherein the fan or propeller assembly includes a gearbox, and wherein the engine core includes one or more rotors, the shaft assembly comprising: a flexible shaft defining a first end and a second end along an axial direction, wherein the first end is connected to the engine core and the second end is connected to the gearbox, and wherein a plurality of splines is defined at the second end and coupled to a spline interface at the gearbox; a coupling extended at least partially in the radial direction and coupled to the engine core and the flexible shaft; and a hub extending generally in the axial direction from a disk of the one or more rotors toward the gearbox, wherein the flexible shaft further defines one or more platforms extended at least partially along the axial direction, wherein the platforms of the flexible shaft contact the hub of the one or more rotors between the first end and the second end of the flexible shaft, and wherein the one or more platforms define an interference fit between the platform and an inner diameter of the hub of the rotor. a flexible shaft defining a first end and a second end along an axial direction, wherein the first end is connected to the engine core and the second end is connected to the gearbox, and wherein a plurality of splines is defined at the second end and coupled to a spline interface at the gearbox; a coupling extended at least partially in the radial direction and coupled to the engine core and the flexible shaft; and a hub extending generally in the axial direction from a disk of the one or more rotors toward the gearbox, wherein the flexible shaft further defines one or more platforms extended at least partially along the axial direction, wherein the platforms of the flexible shaft contact the hub of the one or more rotors between the first end and the second end of the flexible shaft, and wherein the one or more platforms define an interference fit between the platform and an inner diameter of the hub of the rotor.
A compound of Formula I, a tautomer thereof, a racemate or optical isomer thereof, a pharmaceutically acceptable salt or a solvate thereof, wherein: R 1 and R 2 each independently is H, F, Cl, Br, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy,; R 1, R 2 can be same or different, wherein R 1 can represent 1-3 substituents which can be at o-, m- or p-position of benzene ring; R 2 can represent 1-3 substituents; R 3 and R' 3 each independently is H, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy; Y is CH or N, and when Y is CH, R 2 represent at most 3 substituents which can be at 3-, 4-, 5- or 6-position; when Y is N, R 2 represent at most 2 substituents which can be at 4-, 5- or 6-position of heterocyclic ring. R 1 and R 2 each independently is H, F, Cl, Br, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy,; R 1, R 2 can be same or different, wherein R 1 can represent 1-3 substituents which can be at o-, m- or p-position of benzene ring; R 2 can represent 1-3 substituents; R 3 and R' 3 each independently is H, C 1 -C 4 alkyl, or C 1 -C 4 alkoxy; Y is CH or N, and when Y is CH, R 2 represent at most 3 substituents which can be at 3-, 4-, 5- or 6-position;
A pharmaceutical composition for use in a method of treating a subject with dry-form age-related macular degeneration, comprising: administering into the subretina of the subject a therapeutically effective amount of the pharmaceutical composition comprising human retinal pigment epithelium cells, wherein at least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells in a monolayer is greater than 100 ohms to the subject, thereby treating the subject. administering into the subretina of the subject a therapeutically effective amount of the pharmaceutical composition comprising human retinal pigment epithelium cells, wherein at least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells in a monolayer is greater than 100 ohms to the subject, thereby treating the subject.
Optical beam splitter assembly for recording images in at least three different spectral portions (110, 120, 130), comprising a first and a second beam splitter (151, 152), and a first, second and third light path (171, 172, 173), the first light path being configured to guide light of a first spectral portion from a light entrance section to a first light output section, the second light path being configured to guide light of a second spectral portion from the light entrance section to a second light output section, the second light output section being spaced apart from the first light output section, and the third light path being configured to guide light of a third spectral portion from the light entrance section to a third light output section, the third light output section being spaced apart from the first light output section and the second light output section, wherein the second light path traverses the first beam splitter, and the third light path traverses the first and the second beam splitter (151, 152), wherein the optical beam splitter assembly comprises three cameras (181, 182, 183) for detecting the light at the first, second and third output section (161, 162, 163), one camera (181, 182) being a black-and-white camera and two cameras (181, 182, 183) comprising Bayer filters (188a, 188b), wherein the camera (181, 182) associated with either the first light output section or the second light output section is configured to record a color image in a color space, the color space having a predetermined set of color channels and the spectral portion of the first light path comprises two spectral subportions (111, 112), wherein a first subportion overlaps with a first color channel of the color space and not a second color channel of the color space, wherein a second subportion overlaps at least with a second color channel, characterized in that the reflected spectral portion recorded by the black-and-white camera (182, 181) associated with other one of the first light output section and the second light output section lies between the two spectral subportions (111, 112) recorded at the first light output section or the second light output section, respectively.
A method of preparing a thermoplastic resin, the method comprising a coagulation step of adding a water-soluble silicate compound and a metal salt coagulant to an α-methylstyrene-vinyl cyan compound copolymer latex, followed by coagulation, wherein the coagulation step is carried out at a temperature of greater than 80 °C, wherein the water-soluble silicate compound is added after or upon addition of the metal salt coagulant, the method comprising an aging step after the coagulation step, wherein the aging step is carried out at 110 °C or more.
A force sensing device, comprising: a first upper conductive layer and a second lower conductive layer; a pressure sensitive active layer responsive to a mechanical interaction, said pressure sensitive active layer comprising a pressure sensitive material; and a force distribution structure positioned between said first upper conductive layer and said second lower conductive layer, said force distribution structure extending between a first end and a second end of said first upper conductive layer; wherein said force distribution structure is configured to expand the contact area between said pressure sensitive active layer and said first upper conductive layer in response to a force being applied to said force sensing device; characterised in that: said pressure sensitive material is applied to an upper surface of said force distribution structure to form said pressure sensitive active layer. a first upper conductive layer and a second lower conductive layer; a pressure sensitive active layer responsive to a mechanical interaction, said pressure sensitive active layer comprising a pressure sensitive material; and a force distribution structure positioned between said first upper conductive layer and said second lower conductive layer, said force distribution structure extending between a first end and a second end of said first upper conductive layer; wherein said force distribution structure is configured to expand the contact area between said pressure sensitive active layer and said first upper conductive layer in response to a force being applied to said force sensing device; characterised in that: said pressure sensitive material is applied to an upper surface of said force distribution structure to form said pressure sensitive active layer.
A portable surgical visualization kit to assist the viewing of an operator, during surgical procedures to operate a patient, the kit comprising: a camera configured to capture images; viewing equipment including an operator's viewing equipment (120a, 120b) for the operator's viewing, the viewing equipment being configured to receive and display the captured images from the camera, the camera being separated from the operator's viewing equipment (120a, 120b) when in use; and a processor coupled to the camera and the viewing equipment; characterizing in that the kit further comprises a stand for supporting the camera and the processor, the stand being configured for releasable assembly and disassembly; and a case for housing the camera, the viewing equipment, the processor, and the stand, when the stand is in a disassembled configuration and the camera and the processor are removed from the stand; wherein the viewing equipment includes a headset, the viewing equipment also including a visor coupled to the headset, the visor including a pair of digital loupes, the operator's viewing being toggled between a viewing display in the headset from the camera and a viewing display in the headset from the digital loupes, following an operator's action. a camera configured to capture images; viewing equipment including an operator's viewing equipment (120a, 120b) for the operator's viewing, the viewing equipment being configured to receive and display the captured images from the camera, the camera being separated from the operator's viewing equipment (120a, 120b) when in use; and a processor coupled to the camera and the viewing equipment; characterizing in that the kit further comprises a stand for supporting the camera and the processor, the stand being configured for releasable assembly and disassembly; and a case for housing the camera, the viewing equipment, the processor, and the stand, when the stand is in a disassembled configuration and the camera and the processor are removed from the stand; wherein the viewing equipment includes a headset, the viewing equipment also including a visor coupled to the headset, the visor including a pair of digital loupes, the operator's viewing being toggled between a viewing display in the headset from the camera and a viewing display in the headset from the digital loupes, following an operator's action.
In vitro-matured CCR7 + mature human dendritic cells (DCs) obtained by a method comprising the sequential steps of: (a) signaling isolated immature dendritic cells (iDCs) in vitro with a first signal comprising IFN-γ, TNF-α, and PGE 2 to produce signaled mature CD83 + dendritic cells, wherein said immature dendritic cells are prepared from peripheral blood mononuclear cells (PBMCs); and (b) signaling said mature CD83 + dendritic cells in vitro with a second transient signal comprising an effective amount of CD40L to produce CCR7 + CD83 + mature dendritic cells, wherein said second signal is effected upon translation of an mRNA encoding CD40L, and said cells are transfected with said mRNA using electroporation, wherein the electroporation is initiated 12 to 30 hours after the initiation of signaling the DCs with IFN-γ and TNF-α, and wherein the DCs are loaded with an antigen by transfection with a nucleic acid encoding said antigen, said transfection also taking place using electroporation, and further wherein the DCs produce at least 1000 pg IL-12 p70/10 6 DCs and have the capacity to migrate. (a) signaling isolated immature dendritic cells (iDCs) in vitro with a first signal comprising IFN-γ, TNF-α, and PGE 2 to produce signaled mature CD83 + dendritic cells, wherein said immature dendritic cells are prepared from peripheral blood mononuclear cells (PBMCs); and (b) signaling said mature CD83 + dendritic cells in vitro with a second transient signal comprising an effective amount of CD40L to produce CCR7 + CD83 + mature dendritic cells, wherein said second signal is effected upon translation of an mRNA encoding CD40L, and said cells are transfected with said mRNA using electroporation, wherein the electroporation is initiated 12 to 30 hours after the initiation of signaling the DCs with IFN-γ and TNF-α, and wherein the DCs are loaded with an antigen by transfection with a nucleic acid encoding said antigen, said transfection also taking place using electroporation, and further wherein the DCs produce at least 1000 pg IL-12 p70/10 6 DCs and have the capacity to migrate.
A recording medium comprising a recording medium substrate, a first ink receiving layer on the recording medium substrate, and a second ink receiving layer on the first ink receiving layer, wherein the first ink receiving layer is in contact with the second ink receiving layer; characterized in that the first ink receiving layer comprises an alumina hydrate and a hydroxy acid; and the second ink receiving layer comprises an alumina hydrate and a sulfonic acid. the first ink receiving layer is in contact with the second ink receiving layer; characterized in that the first ink receiving layer comprises an alumina hydrate and a hydroxy acid; and the second ink receiving layer comprises an alumina hydrate and a sulfonic acid.